海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
334件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-05-16
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-04-12
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-03-05
Authorised
- A placebo-controlled study to assess efficacy, safety, tolerability and PK/PD of MOR106 in subjects with moderate to severe atopic dermatitis
- atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Denmark, Germany, Hungary, Poland, Spain, United Kingdom
- 2018-03-02
Authorised
- Investigation of efficacy of Secukinumab in patients with moderate to serve atopic dermatitis
- Moderate to serve atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Germany
- 2018-01-26
Authorised
- Is treatment with emollients always beneficial? Comparative biophysical and molecularbiological studies of the skinbarrier function in patients with atopic dermatitis, ichtyosis vulgaris and x-linked ichtyosis.
- Patients with Atopic Dermatitis, Ichtyosis vulgaris and X-linked Ichtyosis
- Sweden
- 2009-07-08
Authorised
- Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinorésistance et traités par bithérapie interféron pégylé ribavirine. - PEGLIST
- Chronic hepatitis C Insulin resistance MedDRA version: 11.1 Level: LLT Classification code 10008912 Term: MedDRA version: 11.1 Level: LLT Classification code 10022489 Term:
- France
- 2009-04-28
Authorised
- Efficacy of topical coal tar in children with atopic dermatitis
- Atopic dermatitis MedDRA version: 19.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Netherlands
- 2017-01-25
Authorised
- Additional effect of topical coal tar in adults with atopic dermatitis.
- Atopic Dermatitis (AD) MedDRA version: 19.1 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Netherlands
- 2017-01-25
Authorised
- A multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabetes
- Type II diabetes mellitus.
- Czech Republic, Germany, Hungary, Spain, United Kingdom
- 2006-01-24